Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance

PEGylated liposomes are known to exhibit accelerated clearance from systemic circulation on repeat administration (the so‐called “accelerated blood clearance” or ABC effect); however, little is known about this effect for other PEGylated colloidal drug delivery systems. Furthermore, our understandin...

Full description

Saved in:
Bibliographic Details
Published inJournal of pharmaceutical sciences Vol. 100; no. 11; pp. 5069 - 5077
Main Authors Kaminskas, Lisa M., Mcleod, Victoria M., Porter, Christopher J.H., Boyd, Ben J.
Format Journal Article
LanguageEnglish
Published Hoboken Elsevier Inc 01.11.2011
Wiley Subscription Services, Inc., A Wiley Company
Wiley
American Pharmaceutical Association
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
Abstract PEGylated liposomes are known to exhibit accelerated clearance from systemic circulation on repeat administration (the so‐called “accelerated blood clearance” or ABC effect); however, little is known about this effect for other PEGylated colloidal drug delivery systems. Furthermore, our understanding of the mechanisms by which the ABC effect is induced is limited. This article further addresses these issues by examining the impact of colloid types [polyethylene glycol (PEG)–liposomes, PEG–micelles] of varying sizes on the appearance of the ABC effect when readministered 7 days after a “priming” dose. Intravenous injection of PEG–liposomes and putative PEG–micelles induced the production of anti‐PEG immunoglobulin (Ig) M, although decreasing the average particle size led to reduced IgM titres. The ABC effect was observed for PEGylated phospholipid/cholesterol‐based liposomes 7 days after an initial “priming” dose of liposome; however, addition of increasing levels of PEGylated lipid to form micelles reduced the propensity of observation of the ABC effect, correlating with the reduced IgM production. The results suggest that although PEG–micelles may stimulate limited production of anti‐PEG IgM, which leads to accelerated clearance of subsequently administered PEG–liposomes, PEGylated micelles themselves are not substrates for IgM binding and do not exhibit a similar ABC. © 2011 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:5069–5077, 2011
AbstractList PEGylated liposomes are known to exhibit accelerated clearance from systemic circulation on repeat administration (the so‐called “accelerated blood clearance” or ABC effect); however, little is known about this effect for other PEGylated colloidal drug delivery systems. Furthermore, our understanding of the mechanisms by which the ABC effect is induced is limited. This article further addresses these issues by examining the impact of colloid types [polyethylene glycol (PEG)–liposomes, PEG–micelles] of varying sizes on the appearance of the ABC effect when readministered 7 days after a “priming” dose. Intravenous injection of PEG–liposomes and putative PEG–micelles induced the production of anti‐PEG immunoglobulin (Ig) M, although decreasing the average particle size led to reduced IgM titres. The ABC effect was observed for PEGylated phospholipid/cholesterol‐based liposomes 7 days after an initial “priming” dose of liposome; however, addition of increasing levels of PEGylated lipid to form micelles reduced the propensity of observation of the ABC effect, correlating with the reduced IgM production. The results suggest that although PEG–micelles may stimulate limited production of anti‐PEG IgM, which leads to accelerated clearance of subsequently administered PEG–liposomes, PEGylated micelles themselves are not substrates for IgM binding and do not exhibit a similar ABC. © 2011 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:5069–5077, 2011
PEGylated liposomes are known to exhibit accelerated clearance from systemic circulation on repeat administration (the so-called "accelerated blood clearance" or ABC effect); however, little is known about this effect for other PEGylated colloidal drug delivery systems. Furthermore, our understanding of the mechanisms by which the ABC effect is induced is limited. This article further addresses these issues by examining the impact of colloid types [polyethylene glycol (PEG)-liposomes, PEG-micelles] of varying sizes on the appearance of the ABC effect when readministered 7 days after a "priming" dose. Intravenous injection of PEG-liposomes and putative PEG-micelles induced the production of anti-PEG immunoglobulin (Ig) M, although decreasing the average particle size led to reduced IgM titres. The ABC effect was observed for PEGylated phospholipid/cholesterol-based liposomes 7 days after an initial "priming" dose of liposome; however, addition of increasing levels of PEGylated lipid to form micelles reduced the propensity of observation of the ABC effect, correlating with the reduced IgM production. The results suggest that although PEG-micelles may stimulate limited production of anti-PEG IgM, which leads to accelerated clearance of subsequently administered PEG-liposomes, PEGylated micelles themselves are not substrates for IgM binding and do not exhibit a similar ABC.
PEGylated liposomes are known to exhibit accelerated clearance from systemic circulation on repeat administration (the so-called "accelerated blood clearance" or ABC effect); however, little is known about this effect for other PEGylated colloidal drug delivery systems. Furthermore, our understanding of the mechanisms by which the ABC effect is induced is limited. This article further addresses these issues by examining the impact of colloid types [polyethylene glycol (PEG)-liposomes, PEG-micelles] of varying sizes on the appearance of the ABC effect when readministered 7 days after a "priming" dose. Intravenous injection of PEG-liposomes and putative PEG-micelles induced the production of anti-PEG immunoglobulin (Ig) M, although decreasing the average particle size led to reduced IgM titres. The ABC effect was observed for PEGylated phospholipid/cholesterol-based liposomes 7 days after an initial "priming" dose of liposome; however, addition of increasing levels of PEGylated lipid to form micelles reduced the propensity of observation of the ABC effect, correlating with the reduced IgM production. The results suggest that although PEG-micelles may stimulate limited production of anti-PEG IgM, which leads to accelerated clearance of subsequently administered PEG-liposomes, PEGylated micelles themselves are not substrates for IgM binding and do not exhibit a similar ABC. © 2011 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:5069-5077, 2011 [PUBLICATION ABSTRACT]
Author Mcleod, Victoria M.
Boyd, Ben J.
H. Porter, Christopher J.
Kaminskas, Lisa M.
Author_xml – sequence: 1
  givenname: Lisa M.
  surname: Kaminskas
  fullname: Kaminskas, Lisa M.
  organization: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
– sequence: 2
  givenname: Victoria M.
  surname: Mcleod
  fullname: Mcleod, Victoria M.
  organization: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
– sequence: 3
  givenname: Christopher J.H.
  surname: Porter
  fullname: Porter, Christopher J.H.
  organization: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
– sequence: 4
  givenname: Ben J.
  surname: Boyd
  fullname: Boyd, Ben J.
  email: ben.boyd@monash.edu
  organization: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24618106$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21721002$$D View this record in MEDLINE/PubMed
BookMark eNp1kttu1DAQhi1URLeFC14ARUIIcZHWhzhxLqvSLocKKg6CO8uxx6q33nixk8K-PU6zLRKCK9vj759_POMDtNeHHhB6SvARwZgerzbpiNJa0AdoQTjFZY1Js4cW-Y6WjFftPjpIaYUxrjHnj9A-JQ2dlAuUXjtrIUKvIRWuL3TwPjijfJGGOOphjFAEW1yeLbdeDWCKXvVhnXfRKZ8K4_SQD8VwBYV31-DdVQhmUiitwUO81XR-CmoPKqps9Bg9tFkMT3brIfp6fvbl9E158XH59vTkotScYVrWjWBQa14RwokBY1hrVUeNsgwMYzXuOlzxRuhKEWxNq0glRM1ES7glWHTsEL2c825i-DFCGuTapVyVVz2EMUnRVoJUrGky-fwvchXG2OfiZPZuWMawyNSrmdIxpBTByk10axW3kmA5tVPmQcjbQWT22S7j2K3B3JN3nc_Aix2gklbeTp1x6Q9X1UQQXGfueOZ-Og_b_zvKd5ef76zLWeHSAL_uFSpey7phDZffPizlp_eYku-4lZMDm3nIs7hxEGXSbvoQxkXQgzTB_eOBvwFeSsGB
CODEN JPMSAE
CitedBy_id crossref_primary_10_1016_j_ajps_2017_07_003
crossref_primary_10_1016_j_addr_2012_10_014
crossref_primary_10_1007_s10904_014_0143_8
crossref_primary_10_1016_j_ajps_2016_07_003
crossref_primary_10_3390_pharmaceutics12080751
crossref_primary_10_1021_acs_chemrev_8b00199
crossref_primary_10_1016_j_ajps_2016_06_004
crossref_primary_10_1208_s12249_020_1640_4
crossref_primary_10_1016_j_jconrel_2016_01_041
crossref_primary_10_1016_j_ultrasmedbio_2018_02_006
crossref_primary_10_1208_s12249_021_02047_1
crossref_primary_10_1016_j_ajps_2014_09_004
crossref_primary_10_1016_j_imbio_2012_08_274
crossref_primary_10_1016_j_jcis_2020_05_120
crossref_primary_10_1021_acs_molpharmaceut_8b00019
crossref_primary_10_1039_D2CS00518B
crossref_primary_10_1016_j_nantod_2023_102032
crossref_primary_10_1208_s12249_020_01838_2
crossref_primary_10_1007_s11095_013_1067_7
crossref_primary_10_1016_j_addr_2017_08_010
crossref_primary_10_1038_clpt_2013_174
crossref_primary_10_1021_acsnano_0c08913
crossref_primary_10_1021_acs_molpharmaceut_5b00144
crossref_primary_10_1016_j_nantod_2024_102255
crossref_primary_10_1016_j_jcis_2012_10_014
crossref_primary_10_1016_j_cocis_2020_101408
crossref_primary_10_1093_rb_rbv003
crossref_primary_10_1021_acs_molpharmaceut_3c00104
crossref_primary_10_1021_acs_molpharmaceut_3c00102
crossref_primary_10_1016_j_addr_2021_114079
crossref_primary_10_1248_bpb_b12_00276
crossref_primary_10_1039_c2cs15344k
crossref_primary_10_1021_acs_bioconjchem_3c00174
crossref_primary_10_1039_C3TX50075F
crossref_primary_10_1016_j_addr_2023_115044
crossref_primary_10_1016_j_biomaterials_2011_12_018
crossref_primary_10_1007_s13346_018_0588_3
crossref_primary_10_1016_j_taap_2014_03_002
crossref_primary_10_3390_nano10091649
crossref_primary_10_1021_acsnano_1c05922
crossref_primary_10_1016_j_xphs_2023_11_001
crossref_primary_10_1021_ml500112u
crossref_primary_10_1016_j_ejpb_2012_04_023
crossref_primary_10_1016_j_biomaterials_2021_121140
crossref_primary_10_1248_bpb_b14_00653
crossref_primary_10_1038_gt_2014_32
crossref_primary_10_1016_j_ijpharm_2012_07_049
crossref_primary_10_1016_j_taap_2016_01_005
crossref_primary_10_1021_nn405830g
crossref_primary_10_3109_02652048_2012_658445
crossref_primary_10_3109_1061186X_2015_1034280
crossref_primary_10_1002_adma_202309355
crossref_primary_10_1016_j_ejpb_2013_10_002
crossref_primary_10_1021_acs_biomac_0c00765
crossref_primary_10_1080_08982104_2017_1391285
crossref_primary_10_3389_fbioe_2022_879988
crossref_primary_10_1002_wnan_1339
crossref_primary_10_1016_j_jconrel_2014_04_003
crossref_primary_10_1021_mp5006189
crossref_primary_10_1002_advs_201801223
crossref_primary_10_1038_s44222_023_00138_1
Cites_doi 10.1016/j.jconrel.2006.01.005
10.1016/j.jconrel.2006.08.017
10.1016/j.ijpharm.2008.06.004
10.1016/j.jconrel.2005.04.003
10.1016/j.jconrel.2005.01.008
10.1021/mp060032e
10.1016/S0168-3659(02)00462-5
10.3390/pharmaceutics3010001
10.1016/j.jconrel.2007.02.010
10.1007/s11095-009-9943-x
10.1016/j.ijpharm.2010.03.022
10.1124/jpet.104.078113
10.1016/S0006-3495(97)78066-4
10.1016/j.jconrel.2009.08.005
10.1016/j.ejpb.2008.11.010
10.1002/jps.20150
10.1023/A:1020488012264
ContentType Journal Article
Copyright 2011 Wiley-Liss, Inc.
Copyright © 2011 Wiley‐Liss, Inc.
2015 INIST-CNRS
Copyright © 2011 Wiley-Liss, Inc.
Copyright_xml – notice: 2011 Wiley-Liss, Inc.
– notice: Copyright © 2011 Wiley‐Liss, Inc.
– notice: 2015 INIST-CNRS
– notice: Copyright © 2011 Wiley-Liss, Inc.
DBID BSCLL
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QO
7QP
7QR
7TK
7U7
8FD
C1K
FR3
P64
RC3
7X8
DOI 10.1002/jps.22682
DatabaseName Istex
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Biotechnology Research Abstracts
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Neurosciences Abstracts
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Genetics Abstracts
Biotechnology Research Abstracts
Technology Research Database
Toxicology Abstracts
Chemoreception Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList

MEDLINE
MEDLINE - Academic
Genetics Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1520-6017
EndPage 5077
ExternalDocumentID 3278475401
10_1002_jps_22682
21721002
24618106
JPS22682
ark_67375_WNG_RK021X09_6
S0022354915318608
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1CY
1L6
1OC
1ZS
31~
33P
36B
3O-
3WU
4.4
457
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
A8Z
AAEVG
AAHHS
AAIAV
AAKUH
AALRI
AAOIN
AAONW
AAXUO
AAYOK
AAZKR
ABCQN
ABEML
ABFRF
ABIJN
ABJNI
ABMAC
ABOCM
ABPVW
ABWRO
ACBWZ
ACCFJ
ACGFO
ACGFS
ACIWK
ACPRK
ACSCC
ACXME
ACXQS
ADBBV
ADIZJ
AEEZP
AEFWE
AEIMD
AENEX
AEQDE
AEUQT
AFBPY
AFFNX
AFRAH
AFTJW
AFZJQ
AGHFR
AI.
AITUG
AIWBW
AJAOE
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
AMBMR
AMRAJ
ATUGU
AZBYB
BAFTC
BDRZF
BFHJK
BNHUX
BROTX
BRXPI
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR2
DU5
E3Z
EBD
EBS
EJD
EMB
EMOBN
ESTFP
F00
F01
F04
F5P
FDB
FEDTE
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HF~
HHY
HHZ
HOLLA
HVGLF
HX~
HZ~
IX1
J0M
JPC
KQQ
L7B
LAW
LC2
LC3
LH4
LP6
LP7
LSO
LW6
M41
M6Q
MK0
MK4
N04
N05
N9A
NF~
NNB
O66
O9-
P2P
P2X
P4D
Q.N
Q11
QB0
QRW
R.K
RNS
ROL
RWI
RX1
RYL
SSZ
SUPJJ
SV3
UB1
UKR
UNMZH
V2E
V8K
VH1
W8V
W99
WBFHL
WH7
WIB
WJL
WQJ
WRC
WUP
WWP
WYUIH
XG1
XPP
XV2
Y6R
YCJ
ZE2
ZGI
ZXP
~IA
~WT
ADVLN
AFJKZ
AKRWK
BSCLL
OIG
08R
ABPTK
IQODW
1OB
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QO
7QP
7QR
7TK
7U7
8FD
C1K
FR3
P64
RC3
7X8
ID FETCH-LOGICAL-c5302-6783e6c541151dedd39fab2daf3ed3360bb04578c4a10fd9a1488638915f108b3
IEDL.DBID DR2
ISSN 0022-3549
IngestDate Fri Oct 25 05:41:41 EDT 2024
Thu Oct 10 22:07:31 EDT 2024
Thu Sep 26 16:21:23 EDT 2024
Sat Sep 28 07:48:48 EDT 2024
Sun Oct 22 16:05:25 EDT 2023
Sat Aug 24 00:55:03 EDT 2024
Wed Oct 30 09:47:55 EDT 2024
Fri Feb 23 02:33:56 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords polyethylene glycol
micelle
lipids/lipoproteins
accelerated blood clearance
pharmacokinetics
formulation
clearance
liposome
Biological fluid
Pharmaceutical technology
Liposome
Micelle
Lipids
Clearance
Lipoprotein
Blood
Ethylene oxide polymer
Cyclic ether polymer
Formulation
Pegylated form
Pharmacokinetics
Language English
License CC BY 4.0
Copyright © 2011 Wiley-Liss, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5302-6783e6c541151dedd39fab2daf3ed3360bb04578c4a10fd9a1488638915f108b3
Notes ark:/67375/WNG-RK021X09-6
ArticleID:JPS22682
istex:A37F9852681ED0C7B47DAF73FA2E67DF2C0BB469
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 21721002
PQID 1517381408
PQPubID 1006386
PageCount 9
ParticipantIDs proquest_miscellaneous_894814377
proquest_journals_1517381408
crossref_primary_10_1002_jps_22682
pubmed_primary_21721002
pascalfrancis_primary_24618106
wiley_primary_10_1002_jps_22682_JPS22682
istex_primary_ark_67375_WNG_RK021X09_6
elsevier_sciencedirect_doi_10_1002_jps_22682
PublicationCentury 2000
PublicationDate November 2011
PublicationDateYYYYMMDD 2011-11-01
PublicationDate_xml – month: 11
  year: 2011
  text: November 2011
PublicationDecade 2010
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: Washington, DC
– name: Hoboken, NJ
– name: United States
– name: Washington
PublicationTitle Journal of pharmaceutical sciences
PublicationTitleAlternate J. Pharm. Sci
PublicationYear 2011
Publisher Elsevier Inc
Wiley Subscription Services, Inc., A Wiley Company
Wiley
American Pharmaceutical Association
Elsevier Limited
Publisher_xml – name: Elsevier Inc
– name: Wiley Subscription Services, Inc., A Wiley Company
– name: American Pharmaceutical Association
– name: Wiley
– name: Elsevier Limited
References Ishihara, Takeda, Sakamoto, Kimoto, Kobayashi, Takasaki, Yuki, Tanaka, Takenaga, Igarashi, Maeda, Yamakawa, Okamoto, Otsuka, Ishida, Kiwada, Mizushima, Mizushima (bb0070) 2009; 26
Ishida, Maeda, Ichihara, Irimura, Kiwada (bb0020) 2003; 88
Laverman, Brouwers, Dams, Oyen, Storm, Rooijen, Corstens, Boerman (bb0010) 2000; 293
Edwards, Johnsson, Karlsson, Silvander (bb0105) 1997; 73
Ishida, Atobe, Wang, Kiwada (bb0035) 2006; 115
Ashok, Arleth, Hjelm, Rubinstein, Onyuksel (bb0085) 2004; 93
Kaminskas, Kota, McLeod, Kelly, Karellas, Porter (bb0080) 2009; 140
Wang, Ishida, Ichihara, Kiwada (bb0025) 2005; 104
Boyd, Kaminskas, Karellas, Krippner, Lessene, Porter (bb0090) 2006; 3
Wang, Ishida, Kiwada (bb0045) 2007; 119
Semple, Harasym, Clow, Ansell, Klimuk, Hope (bb0065) 2005; 312
Koide, Asai, Hatanaka, Urakami, Ishii, Kenjo, Nishihara, Yokoyama, Ishida, Kiwada, Oku (bb0055) 2008; 362
Ishida, Ichihara, Wang, Yamamoto, Kimura, Majima, Kiwada (bb0050) 2006; 112
Dams, Laverman, Oyen, Storm, Scherphof, van der Meer, Corstens, Boerman (bb0015) 2000; 292
Laverman, Carstens, Boerman, Dams, Oyen, Rooijen, Corstens, Storm (bb0040) 2001; 298
Maeda, Bharate, Daruwalla (bb0075) 2008; 71
Koide, Asai, Hatanaka, Akai, Ishii, Kenjo, Ishida, Kiwada, Tsukada, Oku (bb0030) 2010; 392
Lukyanov, Gao, Mazzola, Torchilin (bb0095) 2002; 19
Ishida, Harada, Wang, Ichihara, Irimura, Kiwada (bb0060) 2005; 105
Ichihara, Shimizu, Imoto, Hashiguchi, Uehara, Ishida, Kiwada (bb0100) 2011; 3
Dams E, Laverman P, Oyen W, Storm G, Scherphof G, van der Meer J, Corstens F, Boerman O. 2000. Accelerated blood clearance and altered biodistribution of repeat injections of sterically stabilized liposomes. J Pharmacol Exp Ther 292:1071-1079.
Wang XY, Ishida T, Ichihara M, Kiwada H. 2005. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats. J Control Release 104:91-102.
Ishida T, Maeda R, Ichihara M, Irimura K, Kiwada H. 2003. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release 88:35-42.
Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, Kiwada H. 2006. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 112:15-25.
Edwards K, Johnsson M, Karlsson G, Silvander M. 1997. Effect of polyethylene glycol-phospholipids on aggregate structure in preparations of small unilamellar liposomes. Biophys J 73:258-266.
Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ. 2005. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J Pharmacol Exp Ther 312:1020-1026.
Kaminskas LM, Kota J, McLeod VM, Kelly BD, Karellas P, Porter CJ. 2009. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats. J Control Release 140:108-116.
Koide H, Asai T, Hatanaka K, Urakami T, Ishii T, Kenjo E, Nishihara M, Yokoyama M, Ishida T, Kiwada H, Oku N. 2008. Particle size-dependent triggering of accelerated blood clearance phenomenon. Int J Pharm 362:197-200.
Ichihara M, Shimizu T, Imoto A, Hashiguchi Y, Uehara Y, Ishida T, Kiwada H. 2011. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics 3:1-11.
Ashok B, Arleth L, Hjelm RP, Rubinstein I, Onyuksel H. 2004. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: Effects of PEG chain length and PC incorporation. J Pharm Sci 93:2476-2487.
Lukyanov AN, Gao Z, Mazzola L, Torchilin VP. 2002. Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharm Res 19:1424-1429.
Koide H, Asai T, Hatanaka K, Akai S, Ishii T, Kenjo E, Ishida T, Kiwada H, Tsukada H, Oku N. 2010. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int J Pharm 392:218-223.
Ishida T, Harada M, Wang XY, Ichihara M, Irimura K, Kiwada H. 2005. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release 105:305-317.
Boyd BJ, Kaminskas LM, Karellas P, Krippner G, Lessene R, Porter CJH. 2006. Cationic poly-l-lysine dendrimers: Pharmacokinetics, biodistribution and evidence for metabolism and bioresorption after intravenous administration in rats. Mol Pharm 3:614-627.
Wang XY, Ishida T, Kiwada H. 2007. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 119:236-244.
Laverman P, Brouwers AH, Dams ETM, Oyen WJG, Storm G, Rooijen NV, Corstens FHM, Boerman OC. 2000. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J Pharmacol Exp Ther 293:996-1001.
Laverman P, Carstens MG, Boerman OC, Dams ETM, Oyen WJG, Rooijen NV, Corstens FHM, Storm G. 2001. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 298:607-612.
Ishida T, Atobe K, Wang XY, Kiwada H. 2006. Accelerated blood clearance of PEGylated liposomes upon repeated injections: Effect of doxorubicin-encapsulation and high-dose first injection. J Control Release 115:251-258.
Maeda H, Bharate GY, Daruwalla J. 2008. Polymeric drugs for tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 71:409-419.
Ishihara T, Takeda M, Sakamoto H, Kimoto A, Kobayashi C, Takasaki N, Yuki K, Tanaka K, Takenaga M, Igarashi R, Maeda T, Yamakawa N, Okamoto Y, Otsuka M, Ishida T, Kiwada H, Mizushima Y, Mizushima T. 2009. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm Res 26:2270-2279.
2001; 298
1997; 73
2007; 119
2004; 93
2002; 19
2005; 312
2005; 104
2005; 105
2000; 292
2000; 293
2010; 392
2006; 3
2009; 140
2006; 115
2011; 3
2008; 362
2008; 71
2006; 112
2009; 26
2003; 88
Dams (10.1002/jps.22682_bb0015) 2000; 292
Ishida (10.1002/jps.22682_bb0035) 2006; 115
Semple (10.1002/jps.22682_bb0065) 2005; 312
Lukyanov (10.1002/jps.22682_bb0095) 2002; 19
Ichihara (10.1002/jps.22682_bb0100) 2011; 3
Koide (10.1002/jps.22682_bb0055) 2008; 362
Ishihara (10.1002/jps.22682_bb0070) 2009; 26
Maeda (10.1002/jps.22682_bb0075) 2008; 71
Koide (10.1002/jps.22682_bb0030) 2010; 392
Wang (10.1002/jps.22682_bb0045) 2007; 119
Ishida (10.1002/jps.22682_bb0060) 2005; 105
Ishida (10.1002/jps.22682_bb0020) 2003; 88
Laverman (10.1002/jps.22682_bb0040) 2001; 298
Kaminskas (10.1002/jps.22682_bb0080) 2009; 140
Laverman (10.1002/jps.22682_bb0010) 2000; 293
Edwards (10.1002/jps.22682_bb0105) 1997; 73
Wang (10.1002/jps.22682_bb0025) 2005; 104
Ishida (10.1002/jps.22682_bb0050) 2006; 112
Boyd (10.1002/jps.22682_bb0090) 2006; 3
Ashok (10.1002/jps.22682_bb0085) 2004; 93
References_xml – volume: 298
  start-page: 607
  year: 2001
  end-page: 612
  ident: bb0040
  article-title: Factors affecting the accelerated blood clearance of polyethylene glycol–liposomes upon repeated injection
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Storm
– volume: 93
  start-page: 2476
  year: 2004
  end-page: 2487
  ident: bb0085
  article-title: characterization of PEGylated phospholipid micelles for improved drug solubilization: Effects of PEG chain length and PC incorporation
  publication-title: J Pharm Sci
  contributor:
    fullname: Onyuksel
– volume: 73
  start-page: 258
  year: 1997
  end-page: 266
  ident: bb0105
  article-title: Effect of polyethylene glycol–phospholipids on aggregate structure in preparations of small unilamellar liposomes
  publication-title: Biophys J
  contributor:
    fullname: Silvander
– volume: 104
  start-page: 91
  year: 2005
  end-page: 102
  ident: bb0025
  article-title: Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats
  publication-title: J Control Release
  contributor:
    fullname: Kiwada
– volume: 3
  start-page: 1
  year: 2011
  end-page: 11
  ident: bb0100
  article-title: Anti‐PEG IgM response against PEGylated liposomes in mice and rats
  publication-title: Pharmaceutics
  contributor:
    fullname: Kiwada
– volume: 115
  start-page: 251
  year: 2006
  end-page: 258
  ident: bb0035
  article-title: Accelerated blood clearance of PEGylated liposomes upon repeated injections: Effect of doxorubicin‐encapsulation and high‐dose first injection
  publication-title: J Control Release
  contributor:
    fullname: Kiwada
– volume: 293
  start-page: 996
  year: 2000
  end-page: 1001
  ident: bb0010
  article-title: Preclinical and clinical evidence for disappearance of long‐circulating characteristics of polyethylene glycol liposomes at low lipid dose
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Boerman
– volume: 88
  start-page: 35
  year: 2003
  end-page: 42
  ident: bb0020
  article-title: Accelerated clearance of PEGylated liposomes in rats after repeated injections
  publication-title: J Control Release
  contributor:
    fullname: Kiwada
– volume: 119
  start-page: 236
  year: 2007
  end-page: 244
  ident: bb0045
  article-title: Anti‐PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes
  publication-title: J Control Release
  contributor:
    fullname: Kiwada
– volume: 112
  start-page: 15
  year: 2006
  end-page: 25
  ident: bb0050
  article-title: Injection of PEGylated liposomes in rats elicits PEG‐specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes
  publication-title: J Control Release
  contributor:
    fullname: Kiwada
– volume: 71
  start-page: 409
  year: 2008
  end-page: 419
  ident: bb0075
  article-title: Polymeric drugs for tumor‐targeted drug delivery based on EPR‐effect
  publication-title: Eur J Pharm Biopharm
  contributor:
    fullname: Daruwalla
– volume: 105
  start-page: 305
  year: 2005
  end-page: 317
  ident: bb0060
  article-title: Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface‐density and chain length of the first‐dose liposomes
  publication-title: J Control Release
  contributor:
    fullname: Kiwada
– volume: 26
  start-page: 2270
  year: 2009
  end-page: 2279
  ident: bb0070
  article-title: Accelerated blood clearance phenomenon upon repeated injection of PEG‐modified PLA‐nanoparticles
  publication-title: Pharm Res
  contributor:
    fullname: Mizushima
– volume: 140
  start-page: 108
  year: 2009
  end-page: 116
  ident: bb0080
  article-title: PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats
  publication-title: J Control Release
  contributor:
    fullname: Porter
– volume: 392
  start-page: 218
  year: 2010
  end-page: 223
  ident: bb0030
  article-title: T cell‐independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes
  publication-title: Int J Pharm
  contributor:
    fullname: Oku
– volume: 19
  start-page: 1424
  year: 2002
  end-page: 1429
  ident: bb0095
  article-title: Polyethylene glycol–diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice
  publication-title: Pharm Res
  contributor:
    fullname: Torchilin
– volume: 3
  start-page: 614
  year: 2006
  end-page: 627
  ident: bb0090
  article-title: Cationic poly‐l‐lysine dendrimers: Pharmacokinetics, biodistribution and evidence for metabolism and bioresorption after intravenous administration in rats
  publication-title: Mol Pharm
  contributor:
    fullname: Porter
– volume: 312
  start-page: 1020
  year: 2005
  end-page: 1026
  ident: bb0065
  article-title: Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol–lipid conjugates and nucleic acid
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Hope
– volume: 292
  start-page: 1071
  year: 2000
  end-page: 1079
  ident: bb0015
  article-title: Accelerated blood clearance and altered biodistribution of repeat injections of sterically stabilized liposomes
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Boerman
– volume: 362
  start-page: 197
  year: 2008
  end-page: 200
  ident: bb0055
  article-title: Particle size‐dependent triggering of accelerated blood clearance phenomenon
  publication-title: Int J Pharm
  contributor:
    fullname: Oku
– volume: 112
  start-page: 15
  year: 2006
  end-page: 25
  article-title: Injection of PEGylated liposomes in rats elicits PEG‐specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes
  publication-title: J Control Release
– volume: 362
  start-page: 197
  year: 2008
  end-page: 200
  article-title: Particle size‐dependent triggering of accelerated blood clearance phenomenon
  publication-title: Int J Pharm
– volume: 26
  start-page: 2270
  year: 2009
  end-page: 2279
  article-title: Accelerated blood clearance phenomenon upon repeated injection of PEG‐modified PLA‐nanoparticles
  publication-title: Pharm Res
– volume: 119
  start-page: 236
  year: 2007
  end-page: 244
  article-title: Anti‐PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes
  publication-title: J Control Release
– volume: 3
  start-page: 1
  year: 2011
  end-page: 11
  article-title: Anti‐PEG IgM response against PEGylated liposomes in mice and rats
  publication-title: Pharmaceutics
– volume: 93
  start-page: 2476
  year: 2004
  end-page: 2487
  article-title: characterization of PEGylated phospholipid micelles for improved drug solubilization: Effects of PEG chain length and PC incorporation
  publication-title: J Pharm Sci
– volume: 73
  start-page: 258
  year: 1997
  end-page: 266
  article-title: Effect of polyethylene glycol–phospholipids on aggregate structure in preparations of small unilamellar liposomes
  publication-title: Biophys J
– volume: 292
  start-page: 1071
  year: 2000
  end-page: 1079
  article-title: Accelerated blood clearance and altered biodistribution of repeat injections of sterically stabilized liposomes
  publication-title: J Pharmacol Exp Ther
– volume: 298
  start-page: 607
  year: 2001
  end-page: 612
  article-title: Factors affecting the accelerated blood clearance of polyethylene glycol–liposomes upon repeated injection
  publication-title: J Pharmacol Exp Ther
– volume: 115
  start-page: 251
  year: 2006
  end-page: 258
  article-title: Accelerated blood clearance of PEGylated liposomes upon repeated injections: Effect of doxorubicin‐encapsulation and high‐dose first injection
  publication-title: J Control Release
– volume: 312
  start-page: 1020
  year: 2005
  end-page: 1026
  article-title: Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol–lipid conjugates and nucleic acid
  publication-title: J Pharmacol Exp Ther
– volume: 104
  start-page: 91
  year: 2005
  end-page: 102
  article-title: Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats
  publication-title: J Control Release
– volume: 293
  start-page: 996
  year: 2000
  end-page: 1001
  article-title: Preclinical and clinical evidence for disappearance of long‐circulating characteristics of polyethylene glycol liposomes at low lipid dose
  publication-title: J Pharmacol Exp Ther
– volume: 140
  start-page: 108
  year: 2009
  end-page: 116
  article-title: PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats
  publication-title: J Control Release
– volume: 88
  start-page: 35
  year: 2003
  end-page: 42
  article-title: Accelerated clearance of PEGylated liposomes in rats after repeated injections
  publication-title: J Control Release
– volume: 392
  start-page: 218
  year: 2010
  end-page: 223
  article-title: T cell‐independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes
  publication-title: Int J Pharm
– volume: 3
  start-page: 614
  year: 2006
  end-page: 627
  article-title: Cationic poly‐l‐lysine dendrimers: Pharmacokinetics, biodistribution and evidence for metabolism and bioresorption after intravenous administration in rats
  publication-title: Mol Pharm
– volume: 71
  start-page: 409
  year: 2008
  end-page: 419
  article-title: Polymeric drugs for tumor‐targeted drug delivery based on EPR‐effect
  publication-title: Eur J Pharm Biopharm
– volume: 105
  start-page: 305
  year: 2005
  end-page: 317
  article-title: Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface‐density and chain length of the first‐dose liposomes
  publication-title: J Control Release
– volume: 19
  start-page: 1424
  year: 2002
  end-page: 1429
  article-title: Polyethylene glycol–diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice
  publication-title: Pharm Res
– volume: 112
  start-page: 15
  year: 2006
  ident: 10.1002/jps.22682_bb0050
  article-title: Injection of PEGylated liposomes in rats elicits PEG‐specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2006.01.005
  contributor:
    fullname: Ishida
– volume: 115
  start-page: 251
  year: 2006
  ident: 10.1002/jps.22682_bb0035
  article-title: Accelerated blood clearance of PEGylated liposomes upon repeated injections: Effect of doxorubicin‐encapsulation and high‐dose first injection
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2006.08.017
  contributor:
    fullname: Ishida
– volume: 362
  start-page: 197
  year: 2008
  ident: 10.1002/jps.22682_bb0055
  article-title: Particle size‐dependent triggering of accelerated blood clearance phenomenon
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2008.06.004
  contributor:
    fullname: Koide
– volume: 105
  start-page: 305
  year: 2005
  ident: 10.1002/jps.22682_bb0060
  article-title: Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface‐density and chain length of the first‐dose liposomes
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2005.04.003
  contributor:
    fullname: Ishida
– volume: 104
  start-page: 91
  year: 2005
  ident: 10.1002/jps.22682_bb0025
  article-title: Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2005.01.008
  contributor:
    fullname: Wang
– volume: 298
  start-page: 607
  year: 2001
  ident: 10.1002/jps.22682_bb0040
  article-title: Factors affecting the accelerated blood clearance of polyethylene glycol–liposomes upon repeated injection
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Laverman
– volume: 3
  start-page: 614
  year: 2006
  ident: 10.1002/jps.22682_bb0090
  article-title: Cationic poly‐l‐lysine dendrimers: Pharmacokinetics, biodistribution and evidence for metabolism and bioresorption after intravenous administration in rats
  publication-title: Mol Pharm
  doi: 10.1021/mp060032e
  contributor:
    fullname: Boyd
– volume: 88
  start-page: 35
  year: 2003
  ident: 10.1002/jps.22682_bb0020
  article-title: Accelerated clearance of PEGylated liposomes in rats after repeated injections
  publication-title: J Control Release
  doi: 10.1016/S0168-3659(02)00462-5
  contributor:
    fullname: Ishida
– volume: 3
  start-page: 1
  year: 2011
  ident: 10.1002/jps.22682_bb0100
  article-title: Anti‐PEG IgM response against PEGylated liposomes in mice and rats
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics3010001
  contributor:
    fullname: Ichihara
– volume: 293
  start-page: 996
  year: 2000
  ident: 10.1002/jps.22682_bb0010
  article-title: Preclinical and clinical evidence for disappearance of long‐circulating characteristics of polyethylene glycol liposomes at low lipid dose
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Laverman
– volume: 292
  start-page: 1071
  year: 2000
  ident: 10.1002/jps.22682_bb0015
  article-title: Accelerated blood clearance and altered biodistribution of repeat injections of sterically stabilized liposomes
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Dams
– volume: 119
  start-page: 236
  year: 2007
  ident: 10.1002/jps.22682_bb0045
  article-title: Anti‐PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2007.02.010
  contributor:
    fullname: Wang
– volume: 26
  start-page: 2270
  year: 2009
  ident: 10.1002/jps.22682_bb0070
  article-title: Accelerated blood clearance phenomenon upon repeated injection of PEG‐modified PLA‐nanoparticles
  publication-title: Pharm Res
  doi: 10.1007/s11095-009-9943-x
  contributor:
    fullname: Ishihara
– volume: 392
  start-page: 218
  year: 2010
  ident: 10.1002/jps.22682_bb0030
  article-title: T cell‐independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2010.03.022
  contributor:
    fullname: Koide
– volume: 312
  start-page: 1020
  year: 2005
  ident: 10.1002/jps.22682_bb0065
  article-title: Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol–lipid conjugates and nucleic acid
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.104.078113
  contributor:
    fullname: Semple
– volume: 73
  start-page: 258
  year: 1997
  ident: 10.1002/jps.22682_bb0105
  article-title: Effect of polyethylene glycol–phospholipids on aggregate structure in preparations of small unilamellar liposomes
  publication-title: Biophys J
  doi: 10.1016/S0006-3495(97)78066-4
  contributor:
    fullname: Edwards
– volume: 140
  start-page: 108
  year: 2009
  ident: 10.1002/jps.22682_bb0080
  article-title: PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2009.08.005
  contributor:
    fullname: Kaminskas
– volume: 71
  start-page: 409
  year: 2008
  ident: 10.1002/jps.22682_bb0075
  article-title: Polymeric drugs for tumor‐targeted drug delivery based on EPR‐effect
  publication-title: Eur J Pharm Biopharm
  doi: 10.1016/j.ejpb.2008.11.010
  contributor:
    fullname: Maeda
– volume: 93
  start-page: 2476
  year: 2004
  ident: 10.1002/jps.22682_bb0085
  article-title: In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: Effects of PEG chain length and PC incorporation
  publication-title: J Pharm Sci
  doi: 10.1002/jps.20150
  contributor:
    fullname: Ashok
– volume: 19
  start-page: 1424
  year: 2002
  ident: 10.1002/jps.22682_bb0095
  article-title: Polyethylene glycol–diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice
  publication-title: Pharm Res
  doi: 10.1023/A:1020488012264
  contributor:
    fullname: Lukyanov
SSID ssj0006055
Score 2.3452148
Snippet PEGylated liposomes are known to exhibit accelerated clearance from systemic circulation on repeat administration (the so‐called “accelerated blood clearance”...
PEGylated liposomes are known to exhibit accelerated clearance from systemic circulation on repeat administration (the so-called "accelerated blood clearance"...
SourceID proquest
crossref
pubmed
pascalfrancis
wiley
istex
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 5069
SubjectTerms accelerated blood clearance
Biological and medical sciences
clearance
Colloids
formulation
General pharmacology
Immunoglobulin M - immunology
Likelihood Functions
lipids/lipoproteins
liposome
Liposomes
Medical sciences
micelle
Micelles
Nanostructures
Pharmaceutical technology. Pharmaceutical industry
Pharmacokinetics
Pharmacology. Drug treatments
polyethylene glycol
Polyethylene Glycols - chemistry
Title Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance
URI https://dx.doi.org/10.1002/jps.22682
https://api.istex.fr/ark:/67375/WNG-RK021X09-6/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjps.22682
https://www.ncbi.nlm.nih.gov/pubmed/21721002
https://www.proquest.com/docview/1517381408
https://search.proquest.com/docview/894814377
Volume 100
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhvfTSNn26TYMoZelhvbEt27LpqTQvUghLmtA9FIRehu0GO6yzkO2v74xke0lJoPS2sJawxt9ovrFH3xDysbKRUXmkwxyiT5gmPA5VpCFLSSKe6Aw_3bhqi7P85DI9nWWzLfK5Pwvj9SGGF27oGW6_RgeXqt3fiIb-um4nwB0K3H9jxrGc6-B8Ix0FND0blMIhCepVhaJkfxj5UCx6hBa-xTJJ2YKlKt_i4j4OepfSuph09JT87FfjS1EWk9WNmujffwk9_udyn5EnHVelXzy4dsiWrZ-T0dSLXa_H9GJzdqsd0xGdbmSw1y9Ie9D1XoGdiM5riohr5gYm9Jq1q6WlTUWnh8frKyC8htayboA_e5egZq6RB1MgqPRqvoC7RwFmHCG1hli5dGNc3T3V2PsC4fuSXB4dXnw9CbsWD6HGdkUhhEpmc52lQExjY41hZSVVYmTFrGEsj5QCzskLnco4qkwpIXsrkGTFWRVHhWKvyHbd1PYNoWVUWpvF1iQlckSrcs6ZroxRpcwSXgXkQ_-wxbVX8hBeszkRYFzhjBuQcQ8D0VEQTy0EPJH7Lh85qAwTyuUCK-V4Jn6cHYvzb8CgZlEp8oDs3cHSMADl_ApIywOy24NLdLtIK8AmnKEkWREQOvwN_o8fdWRtm1UrCpTbSRnnAXntMbmZG9N7uN-AfHLIenjZ4nT63f14---XviOP3ft1dy5zl2wDdOx7IGg3as954h_wrzZT
link.rule.ids 315,783,787,1378,27936,27937,46306,46730
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Za9tAEB5C8tC-9D7UpulSiumD5eg-oC-lOdwkNSZ1qF_KIu2uwHWQghVD3V_fmV0dpCRQ-iaQdtGO5vhmNfsNwPtCOTKPHGFHGH3swItdO3cEZimeE3sipF83utpiEo0vgpN5ON-Cj-1ZGMMP0W24kWVof00GThvS-z1r6M-reoTgIUEHvIPm7lPjhoPznjwKgXrYcYVjGtTyCjnefjf0rmi0QzL-RYWSWY2yKkyTi9tQ6E1Qq6PS0UP40a7HFKMsR-vrfCR-_0X1-L8LfgQPGrjKPhn9egxbqnwCg6nhu94M2aw_vlUP2YBNeybszVOoD5r2K-iM2KJkpHTVQuKEhrZ2vVKsKtj08HhziZhXsjIrK4TQxiqYXAiCwgwxKrtcLPH1iYOZRmRCYLhc6TG69J4Jan9BGvwMLo4OZ5_HdtPlwRbUscjGaOmrSIQBYlNXKin9tMhyT2aFr6TvR06eI-yMExFkrlPINMMELiGc5YaF6yS5_xy2y6pUL4GlTqpU6CrppQQTVR7FsS8KKfM0C724sOBd-7X5lSHz4Ia22eMoXK6Fa8Gw1QPeoBCDLjh-ktseH2hd6SbMVksqlotD_n1yzM9PEUTNnZRHFuzdUKZuADH6JZiZW7DbahdvHEnNUSaxT6xkiQWsu40ugP7rZKWq1jVPiHEn8OPYghdGKfu5KcPH97Xgg1atu5fNT6bf9MWrf3_0Ldwbz76e8bMvk9PXcF9vt-tjmruwjWqk3iBeu873tFn-ASFWOms
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB5CAqWXNn2rSdOlFNOD5ej9oKfSxEmTYkyaUB8Ki7S7AtdBMlYMdX99Z3b1ICWB0pvB2kU7-nbmG2n2G4D3hXJkHjnCjjD62IEXu3buCMxSPCf2REifbnS1xSQ6vQrOZuFsCz62Z2GMPkT3wo12hvbXtMGXsjjsRUN_LusRcocE_e9OECHzJUZ00WtHIU8PO6lwzIJaWSHHO-yG3heMdsjEv6hOMqvRVIXpcXEXCb3NaXVQGj-GH-1yTC3KYrS-yUfi919Kj_-53l141JBV9smg6wlsqfIpDKZG7XozZJf94a16yAZs2utgb55BfdQ0X0FXxOYlI8hVc4kTGtHa9UqxqmDT45PNNTJeycqsrJBAmz3B5FwQEWbIUNn1fIF3TwrMNCITAoPlSo_RhfdMUPMLwu9zuBofX34-tZseD7agfkU2xkpfRSIMkJm6Uknpp0WWezIrfCV9P3LyHElnnIggc51CphmmbwmxLDcsXCfJ_RewXValegUsdVKlQldJLyWSqPIojn1RSJmnWejFhQXv2ofNl0bKgxvRZo-jcbk2rgXDFga84SCGW3B8InddPtBQ6SbMVgsqlYtD_n1ywi_OkULNnJRHFhzcwlI3gPT8EszLLdhvwcUbN1JztEnskyZZYgHr_kYHQF91slJV65onpLcT-HFswUuDyX5uyu_xfi34oJF1_7L52fSb_vH63y99Cw-mR2P-9cvkfA8e6nft-ozmPmwjitQbJGs3-YHelH8AS305Gg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differences+in+colloidal+structure+of+PEGylated+nanomaterials+dictate+the+likelihood+of+accelerated+blood+clearance&rft.jtitle=Journal+of+pharmaceutical+sciences&rft.au=Kaminskas%2C+Lisa+M.&rft.au=Mcleod%2C+Victoria+M.&rft.au=H.+Porter%2C+Christopher+J.&rft.au=Boyd%2C+Ben+J.&rft.date=2011-11-01&rft.pub=Wiley+Subscription+Services%2C+Inc.%2C+A+Wiley+Company&rft.issn=0022-3549&rft.eissn=1520-6017&rft.volume=100&rft.issue=11&rft.spage=5069&rft.epage=5077&rft_id=info:doi/10.1002%2Fjps.22682&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_RK021X09_6
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3549&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3549&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3549&client=summon